Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan

Neuralstem, Inc. CUR announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan, a wholly owned subsidiary of Sumitomo Corporation Group. Under the agreement, SPI will market development and licensing rights to NSI-189, Neuralstem's neurogenic compound, currently in an FDA-approved Phase I clinical trial for major depression.